****

**Rakovina Therapeutics Inc.**

**Symbol:** TSXV: RKV

**Market Cap:** 12M

**Sector:** Pharmaceutical

**Purpose:** Raise Awareness / Open Market Buying

Rakovina Therapeutics, Inc. was founded in 2020 with a vision to transform and extend the lives of patients with cancer. Our team has deep experience in drug discovery research, preclinical and clinical development and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Our approach centers on using groundbreaking science to create new precision medicines targeting critical DNA damage repair pathway mutations that are the hallmarks of many cancers. We are committed to conducting innovative cutting-edge research with the aim of benefiting patients worldwide.

**Investor Bullet Points:**

* Selected to join a three-year CDN1.3 million (US$975,000) research program funded by St. Baldrick’s Foundation aimed at developing newtreatments for childhood and adolescent bone cancer
* Presented pre-clinical research results at peer-reviewed scientific meetings
* Received notice of allowance for new patents in Canada, the United States and European Union
* Exciting progress from lead optimization activities being conducted in collaboration with the University of British Columbia

**Jeffrey Bacha, Executive Chairman**

Mr. Bacha has been involved in pharmaceutical research and corporate development for more than 25 years as a member of the executive leadership team for multiple companies. Mr. Bacha is the founder and CEO of Edison Oncology Holding Corp., a private corporation which sold assets to establish Rakovina Therapeutics Inc. Prior to founding Edison Oncology, Mr. Bacha co-founded Kintara Therapeutics (NASDAQ: KTRA, formerly DelMar Pharmaceuticals) with Dr. Dennis Brown and served as Chairman and CEO during the company’s growth including the advancement of its lead product candidate to pivotal Phase III clinical trials and NASDAQ listing. Mr. Bacha was served as president and founding CFO of XBiotech, Inc. (NASDAQ: XBIT), founding CEO of Inimex Pharmaceuticals and as of Vice President, Corporate Development at Inflazyme Corp. Programs advanced by Inimex and Inflazyme have become foundational in Soligenix, Inc. (NASDAQ: SNGX) and Aquinox Pharmaceuticals (NASDAQ: AQXP). He is a member of the National Brain Tumor Society Research Roundtable and the Board of the Leukemia Lymphoma Society of Canada. Mr. Bacha currently serves as a consultant to DelMar Pharmaceuticals and Valent Technologies LLC, and as a member of the Board of Directors of Sernova Corp. (TSX-V: SVA). Prior to taking on his operating roles, Mr. Bacha served Senior Manager and Director of KPMG Health Ventures, acting as an advisor to numerous public and private life sciences companies. Mr. Bacha holds an MBA (Hons) from the Goizueta Business School at Emory University (1995) and a degree in BioPhysics from the University of California, San Diego (1991). Mr. Bacha is the inventor or co-inventor on multiple issued U.S. patents and applications, many with foreign counterparts.